Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S1W-08645 · Session 1

Further to the answers to questions S1W-3791 and S1W-5730 by Susan Deacon on 21 January 2000 and 27 April 2000 respectively, whether it wil…

Answered Asked by Mary Scanlon Con Lodged 11 Jul 2000

The question

To ask the Scottish Executive, further to the answers to questions S1W-3791 and S1W-5730 by Susan Deacon on 21 January 2000 and 27 April 2000 respectively, whether it will reconsider its policy on the use of Taxane drugs for the treatment of advanced breast cancer and, in the light of the National Institute for Clinical Excellence guidelines offered to the NHS which recommended that such patients be offered either Taxotere or Taxol in their treatment, whether the Executive will issue similar guidelines to the NHSiS.

The answer

Answered by Susan Deacon on 13 Oct 2000 · 94 days after it was lodged, 73 days after it was due

Taxol and Taxotere are available on the NHS in Scotland and the use of these drugs depends on the clinical judgement of the specialists concerned, informed by any advice issued by their local Drug and Therapeutic Committees.The NICE advice is available to the NHS in Scotland. It will be for the Health Technology Board for Scotland to consider whether they wish to issue further advice directly to the NHS in Scotland.

In the Official Report

No contribution in the Official Report cites S1W-08645 by reference.